Inclusion Criteria:

- Histologically confirmed follicular lymphoma with a biopsy performed in the last 3
months

- Patients previously untreated.

- Patients with at least one of the following symptoms requiring initiation of
treatment:

- Bulky disease at study entry according to the Groupe d'Etudes Lymphomes
Folliculare (GELF) criteria: nodal or extranodal mass > 7cm in its greater
diameter

- B symptoms

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 1

- Elevated serum lactate dehydrogenase (LDH) or beta2-microglobulin

- Involvement of at least 3 nodal sites (each with a diameter greater than 3 cm)

- Symptomatic splenic enlargement

- Compressive syndrome

- Pleural/peritoneal effusion

- Age must be > 18 years and less than 76 years

- Having previously signed a written informed consent form.

Exclusion Criteria:

- Transformation to high-grade lymphoma (secondary to “low-grade” follicular lymphoma).

- Patients without a large tumor burden.

- Patients with prior or concomitant malignancies except non-melanoma skin cancer or
adequately treated in situ cervical cancer.

- Poor renal function: Serum creatinine > 150 μmol/L,

- Known HIV infection or active hepatitis B virus (HBV) or hepatitis C virus (HCV)
infection.

- Patients with contra-indication to interferon, adriamycin, or rituximab.

- Serious underlying medical conditions, which could impair the ability of the patient
to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus,
gastric ulcers, active autoimmune disease). Judgment is up to the investigator.

- Known sensitivity or allergy to murine products

- Adult patient under tutelage.